Literature DB >> 22056177

Effects of tethered ligands and of metal oxidation state on the interactions of cobalt complexes with the 26S proteasome.

Dajena Tomco1, Sara Schmitt, Bashar Ksebati, Mary Jane Heeg, Q Ping Dou, Cláudio N Verani.   

Abstract

In this paper we report on the synthesis and characterization of three cobalt complexes described as [Co(II)(L(1))(2)] (1), [Co(II)(L(2))] (2), and [Co(III)(L(1))(2)]ClO(4)(3). These complexes contain the deprotonated forms of the [NN'O] tridentate ligand HL(1) and its newly synthesized [N(2)N'(2)O(2)] hexadentate counterpart H(2)L(2), namely, 2,4-diiodo-6-((pyridine-2-ylmethylamino)methyl)phenol and 6,6'-((ethane-1,2-diylbis((pyridin-2-ylmethyl) azanediyl))bis(methylene))bis(2,4-diiodophenol). Characterizations for 1-3 include electrospray ionization (ESI) spectrometry, infrared, and UV-visible spectroscopies, and elemental analyses. A detailed (1)H-NMR study was conducted for 3 and X-ray structural data was obtained for 2. The viability of this series as potential agents for proteasome inhibition and cell apoptotic induction involving PC-3 cancer cells is presented comparing the behavior of the untethered [NN'O](2) six-coordinate 1 and 3 and the tethered counterpart 2 with a 1:1 metal-to-ligand ratio. It is observed that the tethering in 2 decreases inhibition activity. When 1 and 3 are compared, the most inert, but redox-active, cobalt(III) species shows the highest chymotrypsin-like activity inhibition on purified proteasome and PC-3 cancer cells. A hypothesis based on the role of oxidation states for proteasome inhibition is offered.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056177      PMCID: PMC3826156          DOI: 10.1016/j.jinorgbio.2011.09.013

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  24 in total

1.  Cellular up-regulation of Nedd4 family interacting protein 1 (Ndfip1) using low levels of bioactive cobalt complexes.

Authors:  Christine Schieber; Jason Howitt; Ulrich Putz; Jonathan M White; Clare L Parish; Paul S Donnelly; Seong-Seng Tan
Journal:  J Biol Chem       Date:  2010-12-27       Impact factor: 5.157

2.  Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts.

Authors:  B An; R H Goldfarb; R Siman; Q P Dou
Journal:  Cell Death Differ       Date:  1998-12       Impact factor: 15.828

3.  Synthesis, characterization and biological activities of mononuclear Co(III) complexes as potential bioreductively activated prodrugs.

Authors:  Elizabeth Teixeira Souza; Lidiane Cavalcante Castro; Frederico Augusto Vieira Castro; Lorenzo do Canto Visentin; Carlos Basílio Pinheiro; Marcos Dias Pereira; Sérgio de Paula Machado; Marciela Scarpellini
Journal:  J Inorg Biochem       Date:  2009-07-16       Impact factor: 4.155

4.  Structural, spectroscopic, and electrochemical behavior of trans-phenolato cobalt(III) complexes of asymmetric NN'O ligands as archetypes for metallomesogens.

Authors:  Rajendra Shakya; Camille Imbert; Hrant P Hratchian; Mauricio Lanznaster; Mary Jane Heeg; Bruce R McGarvey; Marco Allard; H Bernhard Schlegel; Claudio N Verani
Journal:  Dalton Trans       Date:  2006-03-03       Impact factor: 4.390

5.  Electronic effects of electron-donating and -withdrawing groups in model complexes for iron-tyrosine-containing metalloenzymes.

Authors:  Mauricio Lanznaster; Ademir Neves; Adailton J Bortoluzzi; Aline M C Assumpção; Ivo Vencato; Sergio P Machado; Sueli M Drechsel
Journal:  Inorg Chem       Date:  2006-02-06       Impact factor: 5.165

6.  Monitoring disulfide bond formation in the eukaryotic cytosol.

Authors:  Henrik Østergaard; Christine Tachibana; Jakob R Winther
Journal:  J Cell Biol       Date:  2004-07-26       Impact factor: 10.539

Review 7.  Proteasome inhibitors: poisons and remedies.

Authors:  Silke Meiners; Antje Ludwig; Verena Stangl; Karl Stangl
Journal:  Med Res Rev       Date:  2008-03       Impact factor: 12.944

8.  Archetypical modeling and amphiphilic behavior of cobalt(II)-containing soft-materials with asymmetric tridentate ligands.

Authors:  Rajendra Shakya; Sarmad Sahiel Hindo; Libo Wu; Marco M Allard; Mary Jane Heeg; Hrant P Hratchian; Bruce R McGarvey; Sandro R P da Rocha; Claudio N Verani
Journal:  Inorg Chem       Date:  2007-10-17       Impact factor: 5.165

Review 9.  Global approaches to understanding ubiquitination.

Authors:  Peter Kaiser; Lan Huang
Journal:  Genome Biol       Date:  2005-09-29       Impact factor: 13.583

10.  Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.

Authors:  Kenyon G Daniel; Di Chen; Shirley Orlu; Qiuzhi Cindy Cui; Fred R Miller; Q Ping Dou
Journal:  Breast Cancer Res       Date:  2005-09-20       Impact factor: 6.466

View more
  6 in total

1.  Physical properties, ligand substitution reactions, and biological activity of Co(iii)-Schiff base complexes.

Authors:  A Paden King; Hendryck A Gellineau; Samantha N MacMillan; Justin J Wilson
Journal:  Dalton Trans       Date:  2019-05-07       Impact factor: 4.390

Review 2.  Cobalt derivatives as promising therapeutic agents.

Authors:  Marie C Heffern; Natsuho Yamamoto; Robert J Holbrook; Amanda L Eckermann; Thomas J Meade
Journal:  Curr Opin Chem Biol       Date:  2012-12-24       Impact factor: 8.822

3.  A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth.

Authors:  Xiaofen Li; Qingtian Huang; Huidan Long; Peiquan Zhang; Huabo Su; Jinbao Liu
Journal:  EBioMedicine       Date:  2018-12-05       Impact factor: 8.143

4.  Metal-based 2,3-indolinedione derivatives as proteasome inhibitors and inducers of apoptosis in human cancer cells.

Authors:  Pengfei Zhang; Caifeng Bi; Sara M Schmitt; Xin Li; Yuhua Fan; Nan Zhang; Q Ping Dou
Journal:  Int J Mol Med       Date:  2014-07-08       Impact factor: 4.101

5.  Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.

Authors:  Chong Zhao; Xin Chen; Dan Zang; Xiaoying Lan; Siyan Liao; Changshan Yang; Peiquan Zhang; Jinjie Wu; Xiaofen Li; Ningning Liu; Yuning Liao; Hongbiao Huang; Xianping Shi; Lili Jiang; Xiuhua Liu; Zhimin He; Xuejun Wang; Jinbao Liu
Journal:  Biochem Pharmacol       Date:  2016-07-02       Impact factor: 5.858

Review 6.  Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes.

Authors:  Katarzyna Gałczyńska; Zuzanna Drulis-Kawa; Michał Arabski
Journal:  Molecules       Date:  2020-07-31       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.